In summary, our identification of IMPDH2 as a novel prognostic marker and therapeutic target in HB, particularly in cases of metastasis or recurrence, suggests that targeting this factor holds potential to enhance patient prognosis and overall quality of life. The gene discussed is IMPDH2; the disease is hemoglobin measurement.